A Better Future For Families Impacted by Pancreatic Cancer

The GENERATE Study
(GENetic Education, Risk Assessment and TEsting)

The October 8, 2021, edition of the scientific journal Cancer Prevention Research included preliminary data from the GENERATE Study. Funded through the Pancreatic Cancer Collective (PCC), Lustgarten’s strategic collaboration with Stand Up To Cancer (SU2C), the study is investigating the potential impact of improved genetic testing and cancer prevention for those with a first- or second-degree relative with pancreatic cancer. Inherited (genetic) mutations cause approximately 10% of pancreatic cancer cases. GENERATE shows promise for the use of remote tools, such as at-home testing and virtual genetic education and support to reach those at increased risk regardless of proximity to comprehensive cancer treatment facilities.

Check out AGA’s 2/4/2024 Gastroenterology article:
A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study

This project was funded by the Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up To Cancer. The GENERATE Study was conducted by leading pancreatic cancer experts at Dana-Farber Cancer Institute, Johns Hopkins Kimmel Cancer Center, Mayo Clinic, MD Anderson Cancer Center and UC San Diego Moores Cancer Center.